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of patient characteristics and genetic polymorphisms in 
genes coding for enzymes relevant in everolimus PK.
Results Patients who required a dose reduction (n = 18) 
due to toxicity at any time during treatment had significant 
higher everolimus exposures [mean AUC0–24 (SD) 600 (274) 
vs. 395 (129) µg h/L, P = 0.008] than patients without a 
dose reduction (n = 22). A significant association between 
everolimus exposure and stomatitis was found in the four-
level ordered logistic regression analysis (P = 0.047). The 
presence of at least one TTT haplotype in the ABCB1 gene 
was associated with a 21 % decrease in everolimus exposure.
Conclusion The current study showed that dose reductions 
and everolimus-induced stomatitis were strongly associated 
with systemic everolimus drug exposure in patients with can-
cer. Our findings confirm observations from another study in 
patients with cancer and show us that everolimus is a good 
candidate for individualized dosing in patients with cancer.
ClinicalTrial.gov number NCT01118065.
Keywords Everolimus · Exposure–toxicity · Population 
pharmacokinetics · Pharmacogenetics · Individualized 
dosing
Introduction
Everolimus is an orally administered rapamycin derivative 
inhibiting the mammalian target of rapamycin (mTOR) [1]. 
This is a key signaling molecule in the phosphatidylinosi-
tol 3-kinase (PI3K)/Akt pathway which is involved in the 
regulation of growth, proliferation, metabolism, survival 
and angiogenesis of cells and often dysregulated in cancer 
[1]. Currently, everolimus is registered for the treatment of 
advanced hormone receptor positive (HR+), human epi-
dermal growth factor-2 negative (HER2−) breast cancer in 
Abstract 
Background Everolimus is a mTOR inhibitor used for the 
treatment of different solid malignancies. Many patients 
treated with the registered fixed 10 mg dose once daily 
are in need of dose interruptions, reductions or treatment 
discontinuation due to severe adverse events. This study 
determined the correlation between systemic everolimus 
exposure and toxicity. Additionally, the effect of differ-
ent covariates on everolimus pharmacokinetics (PK) was 
explored.
Methods Forty-two patients with advanced thyroid car-
cinoma were treated with 10 mg everolimus once daily. 
Serial pharmacokinetic sampling was performed on days 1 
and 15. Subsequently, a population PK model was devel-
oped using NONMEM to estimate individual PK values 
used for analysis of an exposure–toxicity relationship. Fur-
thermore, this model was used to investigate the influence 
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postmenopausal women in combination with exemestane, 
for metastatic renal cell carcinoma (mRCC), and for irresect-
able or metastatic pancreatic neuroendocrine tumors (pNET) 
and subependymal giant cell astrocytoma (SEGA) [2–4].
Despite its proven efficacy, everolimus is also associated 
with a number of serious side effects. Most common toxici-
ties associated with everolimus therapy include stomatitis, 
rash, fatigue, diarrhea, infections, nausea, loss of appetite, 
hematologic toxicities, dyspnea, noninfectious pneumonitis 
and metabolic abnormalities such as hypercholesterolemia 
and hyperglycemia [5]. While it is reported that the major-
ity of these adverse events are manageable and of mild-to-
moderate severity, many patients are in need of dose inter-
ruptions, reductions or treatment discontinuation due to 
toxicity [6]. Indeed, in the pivotal breast cancer, mRCC and 
pNET phase III trials, 10–35 % of the patients discontinued 
everolimus treatment due to adverse events [2–4]. In addi-
tion, ~62 % of the patients needed dose interruptions or 
reductions compared to 12–29 % in the placebo arms [2, 4].
The large number of dose reductions and treatment dis-
continuation make toxicity currently one of the main chal-
lenges in the optimal use of everolimus for the treatment of 
cancer. In oncology, everolimus is registered as a fixed oral 
dose of 10 mg once daily. However, in transplantation medi-
cine therapeutic drug monitoring (TDM) with individual-
ized dosing is routinely applied due to everolimus’ narrow 
therapeutic window and high inter-patient variability in phar-
macokinetics (PK) [7]. In transplantation medicine, everoli-
mus is used as an immunosuppressant to prevent rejections. 
Dose individualization is not only applied to prevent toxic-
ity, but also to optimize treatment efficacy. In oncology, the 
same high inter-patient variability in PK is seen (AUC; 45 
CV%, Ctrough; 60 CV%) [8]. This substantial variability, in 
combination with the fixed 10 mg dosing, results in large 
differences in everolimus exposure between patients. This 
could result in either supra-therapeutic drug exposure with 
an increased incidence of toxicity, but also in subtherapeutic 
drug exposure leading to decreased anticancer effects.
The primary objective of this study was to assess the 
correlation between everolimus exposure and toxicity in 
patients with advanced thyroid cancer. Additionally, we 
explored the influence of different covariates on everoli-
mus PK, including genetic polymorphisms in genes encod-
ing enzymes involved in the absorption and metabolism of 
everolimus.
Materials and methods
Patients
Forty-two patients were enrolled in this phase II study 
investigating the efficacy and PK of everolimus for the 
treatment of progressive or recurrent, unresectable or met-
astatic thyroid cancer. The efficacy data of this study will 
be reported separately. Participating medical centers were 
the Leiden University Medical Center and the University 
Medical Center Groningen. Patients were treated continu-
ously with everolimus at an once-daily oral dose of 10 mg 
until tumor progression, unacceptable toxicity, death or 
discontinuation from the study for other reasons. Toxici-
ties were assessed at baseline, days 1, 14 and 28 of therapy 
and monthly thereafter according to the National Cancer 
Institute (NCI) Common Terminology Criteria for Adverse 
Events (CTC-AE) version 4.0. Dose adjustments were per-
mitted for adverse events suspected to be related to everoli-
mus. The first dose reduction was to 5 mg once daily. If 
another dose reduction was needed, everolimus was dosed 
as 5 mg every other day. The study was approved by the 
institutional ethics committees (Leiden University Medi-
cal Center and University Medical Center Groningen, the 
Netherlands), and all patients gave written informed con-
sent before entering the study.
Pharmacokinetic sample collection and analysis
For everolimus PK assessment, whole blood samples were 
obtained at days 1 and 15 of therapy. Samples were col-
lected into EDTA tubes at predose and 1, 2 and 3 h after 
everolimus intake (sparse schedule). More extensive PK 
sampling at 4, 5, 6, 7 and 8 h after everolimus intake was 
optional for patients (extensive schedule). Samples were 
stored at −20 °C until the day of analysis.
Everolimus concentrations in whole blood were meas-
ured using a validated ultra performance liquid chroma-
tography-tandem mass spectrometric (UPLC-MS/MS) 
assay. Validation of the assay was performed according to 
the EMA guidelines of bioanalytical method development 
[9]. The calibration line was linear over the range from 2 to 
160 µg/L, and the lower limit of quantification (LLOQ) was 
0.6 µg/L. Assay performance was in agreement with guide-
lines for bioanalytical method development and validation.
Pharmacogenetic analysis
Single‑nucleotide polymorphisms and haplotype selection
Everolimus is metabolized by the cytochrome P450 (CYP) 
enzymes CYP3A4, CYP3A5 and CYP2C8 and is also a sub-
strate for the efflux pump P-glycoprotein (P-gp) encoded by 
the ABCB1 gene [10]. The nuclear pregnane X receptor (PXR; 
NR1I2) regulates the expression of CYP3A4 and could there-
fore also influence everolimus PK [11]. Eleven single-nucle-
otide polymorphisms (SNPs) in these genes were selected 
based upon a candidate gene approach (Supplementary Data 
S1, online). For the ABCB1 and CYP2C8 gene, selected SNPs 
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were used for haplotype analysis performed in gPLINK (Sup-
plementary Data S2, online). Haplotypes were set at a cer-
tainty >0.97. For the ABCB1 and CYP2C8 genes, only haplo-
types and no individual SNPs were tested.
Genotyping assays
Germline DNA was isolated from 400 µl EDTA blood 
using MagNa Pure Compact (Roche, Almere, the Neth-
erlands). DNA concentrations were thereafter measured 
using Nanodrop (Isogen, De Meern, the Netherlands). 
Genotyping was performed using predesigned genotyp-
ing assays (Supplementary Data S1, online). Samples were 
analyzed on a Viia7 real-time PCR system according to the 
manufacturers’ instruction (Life Technologies, Bleiswijk, 
the Netherlands). Call rates of all assays were >98 %. As a 
quality control, at least 5 % of the samples were genotyped 
in duplicate. No inconsistencies were observed. Minor 
allele frequencies (MAF) of all 11 SNPs were calculated 
and compared with reported MAF for European Popula-
tions (HAPMAP). No significant deviations were observed, 
and derived allele frequencies were all in Hardy–Weinberg 
equilibrium (P ≥ 0.05) (Supplementary Data S1, online).
Pharmacokinetic modeling
Base model
Thirty patients completed the extensive PK sampling and ten 
patients the sparse PK sampling schedule. After PK sampling, 
nonlinear mixed-effects modeling (NONMEM) was used to 
describe the population PK of everolimus. Subsequently, the 
developed population PK model was used to estimate individ-
ual everolimus exposure both in terms of AUC0–24 by using 
clearance and with use of the model predicted Ctrough levels. 
NONMEM version 7.2 (Icon Development Solutions, Ellicott 
City, MD, USA) was used with Piranã (version 2.9.0) as the 
modeling environment. Statistical software package R (ver-
sion 2.15.1) was used for handling of data and plot genera-
tion. We also used NONMEM to explore the influence of dif-
ferent covariates on everolimus PK.
A first-order conditional estimation method with inter-
action (FOCE-I) was used to fit models throughout the 
building process. One- and two-compartment models with 
first-order elimination were explored. It was also assessed 
whether there was a change in clearance from day 1 to day 
15 of treatment. Model selection was based on goodness 
of fit and statistical significance. An adjusted model was 
chosen over the original model if the drop in the objec-
tive function value (OFVs) was >3.84 [P < 0.05 with one 
degree of freedom (df), assuming χ2-distribution].
Since the bioavailability (F) of everolimus is unknown, 
F was fixed at 1 and PK parameter estimates reported are 
proportional to F except Ka. In addition, both clearance 
(Cl/F) and the volume of distribution (Vd/F) were allomet-
rically scaled [12].
Covariate analysis
After the base model was determined, covariates were 
tested to explore the influence of bilirubin, aspartate ami-
notransferase (ASAT), alanine aminotransferase (ALAT), 
creatinine, body surface area (BSA) and hematocrit on 
Cl/F. Individual effect sizes were estimated with the for-
mula Cl/Ftypical value = θ1 × (COV/COVmedian)θ2, whereby 
θ1 is the population estimate for Cl/F, COV the tested 
covariate and θ2 the covariant effect size estimate.
The influence of SNPs and haplotypes was all tested as 
a covariate on Cl/F, except for ABCB1 haplotypes which 
were tested for an effect on F as this is physiologically 
more plausible. Effect sizes were estimated with the for-
mula Cl/Ftypical value (or F) = θ1 × θpg12 × θpg23 , whereby θ1 
is the population Cl/F or F estimate in wild-type patients, 
θ2 the covariate effect size of the heterozygote mutation sta-
tus and θ3 the effect size of the homozygote mutation sta-
tus. The heterozygote (pg1) and homozygote (pg2) muta-
tion status was scored as 1 if present or 0 if not present. If 
the genotype frequency was <0.1, homozygote mutant and 
heterozygote mutant genotypes were combined (Supple-
mentary Data S1 and S2, online).
All covariates were first tested for statistical significance 
with univariate forward inclusion into the base model (drop 
in OFV >3.84, df = 1, P < 0.05). After inclusion of signifi-
cant covariates in the intermediate model, a stepwise back-
ward elimination procedure was performed. Covariates 
were remained in the final model if the threshold for sta-
tistical significance of backward elimination was reached 
(increase in OFV >6.64, df = 1, P < 0.01).
Evaluation of model fit
Next to goodness-of-fit plots, a visual predictive check 
(VPC) was used to assess the performance of the final 
model by comparing the 10th and 90th percentiles of the 
simulated concentrations with those of the observed con-
centrations. In addition, a bootstrap analysis was performed 
to evaluate the precision of parameter estimation. Shrink-
age in inter-individual variability and residual errors were 
automatically calculated by NONMEM.
Assessment of systemic exposure toxicity relationship
Selection of toxicities
In this study, all experienced toxicities were scored accord-
ing to CTC-AE version 4.0. However, due to the number of 
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patients included, only a limited number of toxicities were 
selected to be tested for an association with everolimus 
exposure in order to prevent false-positive findings.
We choose dose reductions as the first outcome of toxic-
ity as this is the sum of all different toxicities experienced 
by patients and these are also the toxicities that lead to 
clinical action by the treating physician. In addition, we 
selected stomatitis and pneumonitis as toxicity outcomes. 
The rationale for selection of these toxicities was based 
on their prevalence and the fact that these toxicities are 
(1) objectively measurable, (2) clinically relevant and (3) 
untreatable and therefore leading to dose reductions or dis-
continuation of therapy. Toxicities were scored as the high-
est grade experienced until dose reduction and if no reduc-
tion occurred until the end of study.
Statistical analysis
The difference in day 15 steady-state everolimus exposure 
(AUC0–24 and Ctrough) between patients with and without 
dose reductions was tested with an unpaired t test. The rela-
tionships between day 15 everolimus exposure (AUC0–24 
and Ctrough) and stomatitis and pneumonitis were evaluated 
using a four-level ordered logistic regression in SPSS ver-
sion 20.0 (IBM).
Results
Patient characteristics
Forty-two adult patients with thyroid carcinoma, 22 men 
and 20 women were included in the phase II trial that 
investigated everolimus for the treatment of thyroid can-
cer. Of these patients, 28 (66.7 %) had differentiated, 7 
(16.7 %) had undifferentiated (anaplastic) and 7 (16.7 %) 
had medullary advanced thyroid carcinoma. Two patients 
were excluded for PK analysis; in one patient, no PK sam-
ples were collected, and in the other patient, no measurable 
everolimus levels could be detected. Patient baseline char-
acteristics are shown in Table 1.
Pharmacokinetics
A total of 669 samples from 40 patients were used to build 
the population PK model. The pharmacokinetic data for 
everolimus were best described by a two-compartmental 
model with first-order absorption and first-order elimina-
tion from the central compartment (Supplementary Data 
S3, online). No difference in clearance over time between 
day 1 and day 15 of treatment was found.
Forward inclusion of BSA, creatinine, ASAT, ALAT, 
bilirubin and hematocrit did not improve the PK model, 
and no association between these covariates and clearance 
was found. With forward inclusion of the ABCB1 TTT and 
CCG haplotype, the base model significantly improved 
(ΔOFV = −7.2 and −6.4, respectively, P < 0.05). The other 
SNPs and the CYP2C8 haplotype did not improve the model. 
With multivariate backward elimination, only the presence 
of at least one ABCB1 TTT haplotype remained significant 
(ΔOFV = 9.6, P < 0.01). A 21 % decrease in F was observed 
in the presence of at least one ABCB1 TTT haplotype. Inclu-
sion of this covariate in the final PK model reduced the inter-
patient variability in Cl/F from 38.1 to 35.1 CV%. Parameter 
estimates of the base and final model are shown in Table 2.
Evaluation of the final model was, next to inspection of 
the goodness-of-fit plots, done with VPC and a bootstrap 
procedure. Results of the VPC show that predicted and 
observed concentration intervals are almost identical, indi-
cating accuracy and good predictive performance of the 
final model (Fig. 1). There is a small tendency for a dif-
ference between predicted and observed concentrations in 
the absorption part of the curve due to limited number of 
samples during this phase. Since we mainly used the model 
to estimate individual values for Cl/F, the modest under-
prediction of the absorption did not affect our analysis. The 
Table 1  Patient baseline characteristics
Data are presented as median (range) unless stated otherwise
ALT alanine aminotransferase, ANC absolute neutrophil count, AST 
aspartate aminotransferase, WBC white blood count
Characteristics
N 40
Age (years) 63 (40–80)
Gender (n)
 Male 21 (52.5 %)
 Female 19 (47.5 %)
Length (cm) 173 (154–189)
Weight (kg) 75 (45–105)
Hematology
 WBC (×109/L) 7.1 (3.6–25)
 ANC (×109/L) 4.8 (2.7–13.0)
 Platelets (×109/L) 254 (147–995)
 Hemoglobin (mmol/L) 7.5 (5.3–10.7)
 Hematocrit 0.39 (0.29–0.50)
Chemistry
 AST (U/L) 22 (12–61)
 ALT (U/L) 22 (7–19)
 Creatinine (µmol/L) 66 (42–205)
 Total bilirubin (µmol/L) 9 (4–16)
Tumor type (n)
 Differentiated 26 (65 %)
 Undifferentiated 7 (17.5 %)
 Medullary 7 (17.5 %)
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successful bootstrap procedure with 1000 runs is shown in 
Table 2. The median values for PK parameters found were 
within 10 % of those estimated with the final model, indi-
cating that the model is precise and reliable in its parameter 
estimation.
Exposure–toxicity relationship
The relationships between everolimus exposure and dose 
reductions as well as stomatitis and pneumonitis were 
examined. In total, 45 % of the patients had their everoli-
mus 10 mg dose reduced to a lower dose due to toxicity 
(Table 3). In general, toxicity developed within 3 months 
after the start of everolimus therapy. Toxicities leading to 
dose reduction included stomatitis, pneumonitis, fatigue, 
loss of appetite, diarrhea, liver and kidney toxicity and 
Table 2  Summary of model parameter estimates
Parameter Base model Final model Bootstrap runs
Estimate RSE (%) Shrinkage (%) Estimate RSE (%) Shrinkage (%) Median value 95 % CI
Cl/F (L/h) 20.3 7.0 17.4 8.4 18.0 15.5–20.8
F 1 – 1 – 1 –
V1/F (L) 29.1 18.5 25.2 17.8 25.7 18.1–40.4
ka (h
−1) 0.643 5.3 0.647 6.2 0.653 0.583–0.740
Q (L/h) 60 4.7 51.1 7.3 52.1 45.5–59.1
V2 (L) 475 5.4 400 – 400 –
θTTT on F NA NA 0.792 6.5 % 0.81 0.71–0.90
Inter-individual variability
 Cl/F (CV%) 38.1 % 34.4 10 35.1 % 30.5 11 35.0 % 22.1–49.1 %
 V1/F (CV%) 87.3 % 35.7 27 86.4 % 35.3 27 90.5 % 53.7–138.9 %
Inter-occasion variability
 F (CV%) 20.7 % 37.7 9 19.2 % 38.1 12 19.4 % 12.9–30.5 %
Residual variability
 σ (proportional error) 27.2 % 20.7 7 27.3 % 20.8 7 27.9 % 22.6–32.9 %
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Fig. 1  Visual predictive check (VPC) of final everolimus PK model
Table 3  Dose reductions and toxicity incidence
Dose reductions
 No 22 (55 %)
 Yes 18 (45 %)
Stomatitis
 None 23 (57.5 %)
 Grade 1 12 (30 %)
 Grade 2 2 (5 %)
 Grade 3 3 (7.5 %)
Pneumonitis
 None 36 (90 %)
 Grade 1 2 (5 %)
 Grade 2 1 (2.5 %)
 Grade 3 1 (2.5 %)
Reason for reduction
 Stomatitis 4 (22.2 %)
 Pneumonitis 4 (22.2 %)
 Fatigue 5 (27.8 %)
 Loss of appetite 1 (5.6 %)
 Diarrhea 1 (5.6 %)
 Liver toxicity 1 (5.6 %)
 Kidney toxicity 1 (5.6 %)
 Edema 1 (5.6 %)
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edema. Considering stomatitis, 42.5 % of the patients expe-
rienced any grade stomatitis and 7.5 % experienced grade 3 
stomatitis. In addition, 10 % of the patients had a noninfec-
tious pneumonitis.
Figure 2 shows boxplots of everolimus AUC and Ctrough 
in patients with and without dose reduction. Mean AUC0–
24(SD) and Ctrough were 600 (274) and 395 (129) µg h/L and 
14.9 (9.0) and 8.4 (3.8) µg/L for patients with and without 
dose reductions, respectively. The exposure to everoli-
mus was significantly different between the two groups 
(mean difference in AUC −204 µg h/L (95 % CI −340 
to −69 µg h/L, P = 0.008 and mean difference in Ctrough 
−6.5 µg/L (95 % CI −11.2 to −1.8 P = 0.009). Figure 3 
shows boxplots of AUCs and Ctrough in patients experienc-
ing different grades of stomatitis. A positive association 
between everolimus exposure and stomatitis was identified 
(P = 0.047). The odd ratio for stomatitis was 1.16 (95 % 
CI; 1.06–1.26) for every 50 µg h/L increase in AUC0–24. 
Patients with grade 3 stomatitis had an everolimus exposure 
that was two times that of patients with ≤2 stomatitis 
(AUC0–24 896 vs. 456 µg h/L, P > 0.05 and Ctrough 24.9 vs. 
10.3 µg/L, P > 0.05). No association of everolimus expo-
sure with pneumonitis was found.
Discussion
This study was primarily performed to assess the correla-
tion between everolimus exposure and toxicity. Results 
show that patients who had their everolimus dose reduced 
due to toxicity had significantly higher drug exposures than 
patients without the need for dose reductions. Moreover, 
everolimus exposure was associated with the probability 
for stomatitis and patients with grade 3 stomatitis had an 
everolimus exposure two times that of patients with ≤2 sto-
matitis. Additionally, we found that the presence of at least 
one TTT allele in the ABCB1 gene was associated with 
lower everolimus exposure due to decreased absorption.
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Fig. 2  Boxplot of everolimus exposure in patient with and without 
dose reduction. a AUC0–24 and b Ctrough
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The present findings of a clear relationship between 
everolimus exposure and dose reductions due to toxicity 
and stomatitis are in line with results from other studies in 
patients with cancer treated with everolimus. Previously, 
it has been shown that a twofold increase in everolimus 
exposure increased the risk of ≥grade 3 pulmonary events, 
≥grade 3 stomatitis and ≥grade 3 metabolic events with 
1.9-fold, 1.5-fold and 1.3-fold, respectively, in patients 
with advanced solid tumors [13]. The present analy-
sis could not confirm the earlier identified association of 
everolimus exposure with pneumonitis, but this may be due 
to the limited number of patients with pneumonitis in our 
study cohort.
The fixed 10-mg dosing regimen of everolimus is based 
on its safety profile together with its pharmacodynamic 
effects on the mTOR-dependent pathway in tumor and 
skin biopsies [14, 15]. These studies suggested a dose of 
≥5 or ≥10 mg daily, based on complete inhibition of ser-
ine/threonine kinase p70S6 kinase (S6K1) or phosphoryl-
ated eIF-4G (peIF-4G) which are both downstream targets 
of mTOR. Since inhibition of peIF-4G was only complete 
at the 10-mg dose level, it was advised to use the 10-mg 
once-daily schedule for future clinical studies. The clinical 
relevance of this difference in inhibition of eIF-4G is, how-
ever, unknown and should be further investigated as higher 
dosing introduces also more toxicity.
The present study underscores the high inter-patient 
variability in everolimus PK which is in line with previous 
observations [8]. This is also analog to the variability in PK 
seen for other oral targeted therapies for the treatment of 
cancer such as tyrosine kinase inhibitors (TKIs). For TKIs, 
the evidence for relationships between systemic drug expo-
sure and efficacy or toxicity endpoints is growing [16, 17]. 
The currently available data suggest that an individualized 
dosing approach seems justified in certain circumstances 
and different studies support the feasibility of an individu-
alized dosing approach for TKIs [18, 19].
In the exploration of covariates of influence on everoli-
mus PK, the presence of at least one TTT haplotype was 
responsible for a decrease in everolimus exposure due to 
decreased absorption. Previously, the TTT haplotype has 
been demonstrated to be associated with enhanced function 
of the P-glycoprotein transporter and indeed reduced expo-
sure or efficacy of treatment [20–22]. However, decreased 
function of the transporter and thus increased exposure 
have also been reported, as well as studies that could not 
show an effect [7, 23, 24]. The association we found should 
be regarded as preliminary and needs further validation. If 
this association is confirmed, it might be argued whether a 
decrease in exposure of 21 % can be considered as clini-
cally relevant when taking into account the inter-patient 
variability in everolimus PK.
To the best of our knowledge, we are the first to describe 
the population PK of everolimus 10 mg once daily in 
patient with cancer. Previously, population PK models have 
been described, but only within the field of transplantation 
medicine where everolimus is used in a much lower dose. 
Taking this and differences in modeling into account, phar-
macokinetic parameter estimates were in agreement with 
those previously found [7].
Everolimus exposures were assessed at day 15 of ther-
apy and not necessarily at the time when adverse events 
occurred. This may be considered as a limitation, and future 
studies should preferably measure everolimus exposure at 
the time that toxicity occurs. However, the variability in 
everolimus PK within a patient (intra-patient) is reported 
to be much smaller than the variability between patients 
[25, 26]. In addition, we observed a constant clearance 
of everolimus over time. While treated at the same dose 
(10 mg once daily), this restricts the probability for large 
differences between the exposures that we have measured 
and the actual exposures that would have been measured 
at the moment that toxicity occurred. In addition, the study 
that previously described a correlation between everolimus 
exposure and toxicity found similar results with the use of 
Ctrough at the time of toxicity or when Ctrough averaged over 
a given time period was used [13].
The present results both underscore the correlation 
between everolimus exposure and dose reductions due 
to toxicity as well as the high inter-patient variability in 
everolimus PK. These observations should be taken into 
account in the use of everolimus for the treatment of solid 
tumors. Preventing high drug exposures by dose individual-
ization may have the potential to reduce the side effects of 
everolimus therapy while remaining its efficacy. However, 
prospective validation within oncology patients in neces-
sary. Moreover, it has been shown that high early everoli-
mus exposure (Ctrough >14.1 µg/L) is associated with longer 
progression-free survival (PFS) and overall survival (OS) 
(13.3 and 26.2 vs. 3.9 and 9.9 months for PFS and OS, 
respectively) in patients with mRCC [27]. Hence, an indi-
vidualized dosing approach may also be of value for some 
patients with treatment inefficacy due to subtherapeutic 
exposures. On the other hand, in this present analysis there 
were also patients in need of dose reductions in whom the 
exposure to everolimus was not elevated. This finding sug-
gests that a subpopulation may not benefit from dose indi-
vidualization but maybe more from treatment switch if 
available. In summary, future studies are required to define 
the therapeutic window of everolimus for the treatment of 
different malignancies and these studies should aim to opti-
mize both treatment toxicity and efficacy outcomes possi-
bly by using everolimus in a more individualized way.
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Conclusion
In conclusion, this study shows a clear association between 
everolimus exposure and dose reductions due to toxicity 
as well as stomatitis in patients with cancer using a newly 
developed population PK model. Our findings confirm 
observations from another study in patients with cancer and 
show us that everolimus is a good candidate for individual-
ized dosing in patients with cancer.
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